A CLINICAL STUDY ON AN INTERVENTION IN MALE PARTICIPANTS WITH HAIR LOSS

A Randomised Study to Evaluate the Efficacy and Adverse Effects of Oral Minoxidil and Oral Dutasteride in Androgenetic Alopecia - nil

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/09/095177

Enrollment

Registered

2025-09-22

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L649- Androgenic alopecia, unspecified

Interventions

Intervention1: Tablet Minoxidil: 2.5mg OD oral for 6 months Control Intervention1: Tablet Dutasteride: 0.5mg OD oral for 6 months

Eligibility

Inclusion criteria

Inclusion criteria: All male patients of age group 18 yrs to 60 yrs. Patient who give their consent to the study. Patients with androgenetic alopecia Patient not taking any treatment for androgenetic alopecia since last 6 weeks.

Exclusion criteria

Exclusion criteria: History of usage of anti-androgenic medications, drugs causing hypertrichosis within the past 6 months. Any systemic illnesses including hypertension, cardiomyopathy, nephropathy, dermatosis involving scalp. Hypersensitivity to minoxidil. Smokers or tobacco chewers. History of breast or prostate cancer. History of hair transplantation.

Design outcomes

Primary

Measure	Time frame
To access the increase hair thickness and densityTimepoint: Baseline, 3 months, 6 months	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactBoddeda yashaswini

maharajahs institute of medical sciences

kvtgopal77@gmail.com09440156552

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026